Skip to contentK
Korro Bio, Inc.
K
KRROKorro Bio, Inc. Q1 2022 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2021 Net Income-$23.39M-$23.39MN/M vs Q1 2021 EPS Diluted-$0.67-$0.67N/M vs Q1 2021 Operating Income-$23,258,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
Free Cash Flowderived-$17,355,000N/M ended Mar 31, 2022 · filed May 4, 2022 · 34 d after period end